c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma - Wikidata - awgldk - TriplyDB

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

http://www.wikidata.org/entity/Q36551653

about

Contemporary Treatment of Metastatic Renal Cell Carcinoma Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms Therapeutic challenges in renal cell carcinoma Met in urological cancers Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience Medical treatment of renal cancer: new horizons Choosing the right cell line for renal cell cancer research Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy Cadherin-11 in renal cell carcinoma bone metastasis.Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.MET Inhibition in Clear Cell Renal Cell Carcinoma C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Targeting angiogenesis in renal cell carcinoma.Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.Sequencing systemic therapies for metastatic kidney cancer.A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.Cabozantinib for the treatment of kidney cancer.Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.Cabozantinib for the treatment of renal cell carcinoma.

P2860

Q26740594-5A9EA21D-13E2-4E16-966C-0CD55EF31DE1 Q26741450-3DAB1ECA-DD7A-4CFD-9CE6-1DF4DE2548E4 Q26785930-8CC8E016-B47C-408D-8FC7-4B77BBD2987E Q26796702-0D57575A-F872-484F-BEBE-DC711C8AF114 Q26864988-0E785856-3D59-424D-9674-682EB4F898CD Q28072166-BFAA6D22-39E3-4C0C-9AE9-B939C5431451 Q28073174-893D93C4-2C71-46D2-948A-397F45FFAB9A Q28073283-DC4ECF19-744A-4B1C-98D5-0C612A5B637E Q30382892-8431A9A9-8D7B-419D-A691-C21E1F5F8A65 Q31163345-1A5BAB54-E9B7-4F7B-B1C1-1F489D502C6B Q33769437-B5DA3E58-F803-4ABD-913E-EF1FF4116C07 Q34141440-E5FCEE29-D98A-40A0-9303-FFF98A0CAE93 Q34495684-6C24397E-D02E-4EEB-87D9-76BAD47CB713 Q34964958-066E48DB-ADC3-4AEF-8C3F-C85C06C18395 Q34971882-77A692E2-934D-4601-A159-A667B971C34B Q35108264-5278988E-A9C1-4959-9A19-9392741680CF Q35221521-9A3A04A4-BB45-4FDE-85A1-98B147D5C5BF Q35598471-74B4E9F3-BEFD-4DC1-8CCC-BA9D3BA18758 Q35861046-A7AF3806-056A-4418-913B-BA676DACF8E8 Q36095630-A1A8BE17-D76F-4F4D-8990-0F39C1040EA5 Q36214648-43C878F9-6D16-4F45-BD8C-F570BB9D1380 Q36281483-FC12A630-7DC3-421E-A310-A09921143915 Q36716606-7D8B0FAF-093C-4BA5-A55F-3C7021898805 Q37067981-784B8D0E-A81E-48FB-97DC-D6F03E1B7731 Q37564471-B1D65136-CAD0-4DC1-9185-A06F49CE9774 Q37672483-E61DDEEB-2110-4BAE-A3A2-4BEBD6A0057C Q37702041-E8704E6A-E6B1-4F2F-96FB-122F42312026 Q38132231-4E66256D-C6DF-434B-8207-D9C72FE95298 Q38263575-28EFE5DB-76CF-4C87-8F7C-853C947CDFE5 Q38342983-F955589F-9AC8-4734-946C-2395929C69B9 Q38430335-F444E6CB-CB07-4D92-B231-E7D657B5D904 Q38611436-ED6A7B04-54AF-4C4F-82E8-62F8714ACA6D Q38668871-FDD13CEC-4598-4CA0-871E-E1367A145CA3 Q38746778-4E3BB9A9-62E6-42E8-8C2F-941A1EF6B497 Q38768791-BE0297A8-C865-4CA5-8CDA-B9C41856633F Q38835745-9B9F5C32-F8FE-46BE-94D7-8D2970E42E9F Q38868038-9D24DCF7-893A-4DFF-9483-69FAFCB6B76D Q38947146-F28DFA36-2956-4B7D-B089-A33EB3DBFBA1 Q38950573-7E334DB9-B316-42D1-9B71-4AFBEC213D33 Q39005403-A56162E2-421A-47B0-A2FD-04BC79CB500D

P2860

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

http://www.wikidata.org/entity/Q36551653

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

c-Met is a prognostic marker a ...... lear cell renal cell carcinoma

@ast

c-Met is a prognostic marker a ...... lear cell renal cell carcinoma

@en

type

label

c-Met is a prognostic marker a ...... lear cell renal cell carcinoma

@ast

c-Met is a prognostic marker a ...... lear cell renal cell carcinoma

@en

prefLabel

c-Met is a prognostic marker a ...... lear cell renal cell carcinoma

@ast

c-Met is a prognostic marker a ...... lear cell renal cell carcinoma

@en

P1433

Q36551653-86E9938E-D025-46A0-A638-B7D988816473

P1476

Q36551653-845ED9AD-E569-4634-AAB0-97AA5E22A014

P2093

Q36551653-3B29448D-BE42-4D0E-938B-0255DD92E01C

Q36551653-526AF320-8861-4032-B38F-B88568EC1DB2

Q36551653-81EB3772-38E1-4673-B302-C7D9C651898E

Q36551653-9AD4830B-937F-4B19-97E1-882456A44C9B

Q36551653-9DA36795-2B80-4450-B6B2-118A8F08EBF2

Q36551653-BE272749-049C-4683-96B5-3710C4F297E6

Q36551653-EFB52CFB-8094-402F-837F-82FE8FAD93A3

P2860

Q36551653-06C50134-24B6-4974-ABA6-605105F02EE9

Q36551653-1DCCB18E-0B37-4E48-B376-68C5563218B4

Q36551653-1ED48DCF-8BEF-4F31-BF8A-4EEBF8C278A4

Q36551653-28E81124-5A7D-4AC7-9F14-17FF95F45C9A

Q36551653-3A8EC185-2D00-4F27-B2B1-77DF7B3DD31D

Q36551653-3D9A7AC6-BB3C-4305-9D54-7F82E27DD3F8

Q36551653-43CD151A-00A4-42A8-A3D1-6AC6C98063C2

Q36551653-470EC088-718D-4CAB-9108-F76F4BD13653

Q36551653-47BD463A-97B9-4526-AE7C-D6EB4DBC753B

Q36551653-4CCFC6D7-600B-4A4B-8B44-523715150036

P304

Q36551653-D9FD2FE3-6FBC-4A34-80ED-93A19BA7D1FD

P31

Q36551653-7883CD73-0CDD-414C-B5B9-AF010D56D7D8

P356

Q36551653-CE497499-A3E5-4890-90DF-76B0503C8891

P433

Q36551653-364CD6CB-D9B6-420E-A2DA-D15734CFF062

P478

Q36551653-B510B0B1-1801-42AE-A3C6-EC35ECC86ABC

P50

Q36551653-4EBFA1F0-2B47-4D6F-94F6-F840A3FB39AF

P577

Q36551653-E0EE5CE5-428C-4CB8-8E7E-46A5BD2E43CC

P5875

Q36551653-A8562350-183A-4581-8754-61938E2229F3

P698

Q36551653-9075D5B2-886A-4EE3-807B-631AF005808E

P932

Q36551653-78A338D3-59AA-4803-A46C-405862B179CD

P356

P1433

Annals of Oncology

P1476

c-Met is a prognostic marker a ...... lear cell renal cell carcinoma

@en

P2093

C R Chen

http://www.w3.org/2001/XMLSchema#string

G T Gibney

http://www.w3.org/2001/XMLSchema#string

H M Kluger

http://www.w3.org/2001/XMLSchema#string

P Conrad

http://www.w3.org/2001/XMLSchema#string

R L Camp

http://www.w3.org/2001/XMLSchema#string

S A Aziz

http://www.w3.org/2001/XMLSchema#string

W K Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

Cancer statistics, 2012

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Met, metastasis, motility and more

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

P304

343-349

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDS463

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231612702

http://www.w3.org/2001/XMLSchema#string

P698

23022995

http://www.w3.org/2001/XMLSchema#string

P932

3551486

http://www.w3.org/2001/XMLSchema#string